Illumina (ILMN) is capturing attention following the debut of its proprietary 5-base sequencing solution and impressive results from GeneDx’s pilot of the constellation platform. Both developments were showcased at the American Society for Human Genetics meeting.
See our latest analysis for Illumina.
Illumina’s shares have seen a notable rebound in recent weeks, logging a 9% gain over the last month as investors responded to a flurry of new product launches and encouraging partnerships. However, the stock is still down 24% on a year-to-date share price return basis, and its one-year total shareholder return stands at -29%, reflecting the longer road ahead for a sustained turnaround.
If Illumina’s fresh innovation streak has you watching the sector, it could be the perfect moment to browse other breakthroughs. See the full list of healthcare movers in See the full list for free.
But with Illumina’s fundamentals still recovering and shares trading below analyst price targets, investors are left to consider: is there real upside from here, or is future growth already priced into the stock?
Illumina’s narrative-based fair value estimate lands at $111.95, which is about $12 above the last close of $100.11. This gap spotlights perceived upside in the current share price versus analyst consensus.
Ongoing innovation, multiomics expansion, and operational efficiency are enhancing gross margins and creating new growth opportunities. Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina’s data and platform offerings, contributing to future revenue and operating margin expansion.
Read the complete narrative.
Curious which bold, forward-looking financial shifts power this valuation? The answer lies in a mix of aggressive margin bets, platform scale-up strategies, and the kind of future earnings moves you might not expect. The most debated projections are all embedded here. Click through to discover what really drives this narrative.
Result: Fair Value of $111.95 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent funding constraints and mounting regulatory hurdles in China still pose meaningful risks that could alter Illumina’s long-term trajectory.
Find out about the key risks to this Illumina narrative.
If you see things differently or want to run your own numbers, it’s quick and easy to craft a unique Illumina outlook in just minutes with Do it your way.







